CARNITOR (levocarnitine) by Leadiant Biosciences is clinical pharmacology carnitor (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. First approved in 1992.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
CARNITOR (levocarnitine) is a naturally occurring carnitine analog that facilitates long-chain fatty acid entry into cellular mitochondria for energy production. It is indicated for primary and secondary carnitine deficiency, including End Stage Renal Disease patients on hemodialysis and patients with inborn errors of metabolism such as glutaric aciduria II and propionic acidemia. The drug works by clearing toxic acylCoA compounds through carnitine ester formation and excretion, alleviating metabolic abnormalities.
Product is approaching loss of exclusivity with low competitive pressure (30), indicating a mature brand requiring defensive positioning and potential cost management initiatives.
CLINICAL PHARMACOLOGY CARNITOR (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids…
Worked on CARNITOR at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Carnitine Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CARNITOR offers experience in niche metabolic disease management, healthcare provider relationship building in dialysis and pediatric settings, and defensive brand strategy. Career growth is limited by the mature market and approaching LOE, making this role best suited for professionals seeking specialized expertise in orphan/rare diseases or cost management experience.